The FAP inhibitor sappanchalcone improves carbon tetrachloride-induced liver fibrosis in mice
This study investigates the therapeutic effects of sappanchalcone, a fibroblast activation protein (FAP) inhibitor, on carbon tetrachloride (CCl4)-induced liver fibrosis in mice using transcriptomic analysis. Liver fibrosis is characterized by excessive accumulation of extracellular matrix proteins, and FAP-expressing cells play a crucial role in fibrogenesis. To evaluate the molecular mechanisms underlying sappanchalcone's anti-fibrotic effects, we performed RNA sequencing on liver tissues from CCl4-treated mice with or without sappanchalcone intervention. The transcriptome data provides comprehensive gene expression profiles that reveal differentially expressed genes and pathways involved in the therapeutic response. This dataset will contribute to understanding FAP inhibition as a potential therapeutic strategy for liver fibrosis and provide insights into the molecular targets of sappanchalcone in hepatic pathophysiology.